메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
이한길 (연세대학교) 조현석 (연세대학교) 강혜영 (연세대학교)
저널정보
한국보건의료기술평가학회 보건의료기술평가 보건의료기술평가 제5권 제1호
발행연도
2017.6
수록면
59 - 65 (7page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Objectives: Since cost-effectiveness (CE) is a relative concept in which the incremental costs of a new drug versus comparator treatment are compared with the incremental effects, the choice of a com- parator heavily influences the incremental CE ratio. It has been argued that the selection criteria of comparator treatments suggested by CE guidelines are not well constructed to produce a valid CE as- sessment of drugs. The present study investigated types of potential problems in comparator selection in complying with the Korean CE guideline. Methods: We conducted focus group interviews (FGIs) with experts from drug companies charged with generating and/or submitting CE evidence of their products for reimbursement decisions. To investigate the frequency of the potential problems in the field, we conducted an online survey among those working in drug companies, using a questionnaire developed from the FGI results. Results: Among the six problems identified by the FGIs, the highest proportion of survey respondents experienced “difficulty in obtaining reliable market share data nec- essary to choose comparator treatment” (94%), followed by “drugs widely used for a long time select- ed as comparators because they were recognized as standard treatments” (88%) and “therapeutically nonequivalent drugs selected as comparators” (72%). Conclusion: The results of our investigation would contribute to improving the quality of CE guidelines and the true value assessment of pharma- ceutical interventions.

목차

등록된 정보가 없습니다.

참고문헌 (18)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0